Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Combined Sales of Top-4 Generic-Only Makers Up 15.5%
June 21, 2010
- ASCO 2010 in Chicago (1)
June 21, 2010
- Over 60% of Local Gov't Hospitals Running at a Loss
June 21, 2010
- JGA's Generics Information Supply System Gets on Track
June 21, 2010
- Eribulin Prolongs OS but Not PFS
June 21, 2010
- Leptin Replacement Therapy for Lipoatrophy Recommended as Advanced Therapy
June 21, 2010
- 635 MSs to Take 1 Exam for Certification
June 21, 2010
- Eribulin Shows High ORR in Japanese Patients
June 21, 2010
- Mr Kan Stresses Need for Strong Economy, Strong Finance, and Strong Social Security
June 21, 2010
- NDA Review Period Drastically Shortened in FY2009: PMDA
June 21, 2010
- New c-Met Inhibitor Prolongs PFS in PII for NSCLC
June 21, 2010
- ASCO, FDA Open “Expanded Access”Website on Use of Unapproved Drugs
June 21, 2010
- T-DM1 + Pertuzumab Effective for HER2-Positive Breast Cancer
June 21, 2010
- Benefit-Sharing Based on CBD May Affect Pharma Industry
June 21, 2010
- Roche's Hedgehog Inhibitor Safe in Combination with Standard Chemotherapy
June 21, 2010
- Korosho Issues Memo to Clarify Requirements for Applicants
June 21, 2010
- Avastin Prolongs PFS, but Not OS in PIII in Stomach Cancer
June 21, 2010
- DSP Applies for Changes in Maximum Daily Dose for Meropen
June 21, 2010
- Avastin Effective for HER2-Negative Breast Cancer in Japanese Patients
June 21, 2010
- Add Prevenar to Routine Vaccination Programs in Japan: Mr Kindler
June 21, 2010
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…